The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Morozova M.A.

Centre for Mental Health Research

Potanin S.S.

Centre for Mental Health Research

Burminsky D.S.

Centre for Mental Health Research

Beniashvili A.G.

Centre for Mental Health Research

Rupchev G.E.

Centre for Mental Health Research

Lepilkina T.A.

Centre for Mental Health Research

Sorokin M.Yu.

Bekhterev National Research Center for Psychiatry and Neurology

Kasyanov E.D.

Bekhterev National Medical Research Center for Psychiatry and Neurology

Mazo G.E.

Bekhterev National Medical Research Center for Psychiatry and Neurology

Tarumov D.A.

Kirov Military Medical Academy

Trufanov A.G.

Kirov Military Medical Academy

Markin K.V.

Kirov Military Medical Academy

Beybalaeva T.Z.

Kazan State Medical University

Katok A.A.

Kazan State Medical University

Tsapko D.S.

Sechenov First Moscow State Medical University

Low doses of quetiapine (Seroquel) as an impulsivity corrector in patients with bipolar affective disorder in remission

Authors:

Morozova M.A., Potanin S.S., Burminsky D.S., Beniashvili A.G., Rupchev G.E., Lepilkina T.A., Sorokin M.Yu., Kasyanov E.D., Mazo G.E., Tarumov D.A., Trufanov A.G., Markin K.V., Beybalaeva T.Z., Katok A.A., Tsapko D.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(8): 120‑127

DOI: 10.17116/jnevro2022122081120

Views: 9627

Downloaded: 261

Download PDF (RU)
Contact the author
Table of contents

LOW DOSES OF QUETIAPINE (SEROQUEL) AS AN IMPULSIVITY CORRECTOR IN PATIENTS WITH BIPOLAR AFFECTIVE DISORDER IN REMISSION
LOW DOSES OF QUETIAPINE (SEROQUEL) AS AN IMPULSIVITY CORRECTOR IN PATIENTS WITH BIPOLAR AFFECTIVE DISORDER IN REMISSION

To cite this article:

Morozova MA, Potanin SS, Burminsky DS, et al. . Low doses of quetiapine (Seroquel) as an impulsivity corrector in patients with bipolar affective disorder in remission. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(8):120‑127. (In Russ.)
https://doi.org/10.17116/jnevro2022122081120

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Bipo­lar affe­ctive diso­rder occu­rring with psychopharmacotherapy-induced manic phases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):9-14
Features of cognitive impairment in bipo­lar affe­ctive diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):15-19
Growth factors PDGF-AA, PDGF-BB and BDNF as pote­ntial differentiating biomarkers of unipolar and bipo­lar depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):104-108
The gut microbiota in bipo­lar diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):28-33
Comparative study of cognitive impairment in subgroups of bipo­lar affe­ctive diso­rder types I and II, occu­rring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11

OBJECTIVE

To evaluate the effectiveness of low doses (25-75 mg/day) of quetiapine (Seroquel) in patients with bipolar affective disorders in a euthymic state with signs of impaired impulse control.

MATERIAL AND METHODS

The main criteria for patients’ selection were as follows: both sex, diagnoses of bipolar affective disorders, remission (euthymic state), adult age (from 18 to 60 years old), stable basic therapy. The duration of the study was 6 weeks, a dose of quetiapine (Seroquel) varied from 25 to 75 mg. The examinations were carried out with the Barratt scale, computerized Go-No-Go and Balloon tests.

RESULTS

The study group included 32 patients (11 men and 21 women), mean age 31.2±9.7 years (minimum 18, maximum 60 years). The changes in Barratt total score (p=0.000014, Wilcoxon test, effect size 0.48) and Balloon total earnings (p=0.03, Wilcoxon test, effect size 0.22) were statistically significant and reflected clinically significant improvement. The changes of the indices of the Go-No-Go test were not significant. The data of fMRI showed an increase in the connectivity of the cortex of the central and parietal tegmentum of the left hemisphere with other areas of the brain, which correlated with the changes in psychometric and test parameters.

CONCLUSION

The results of the study showed that add-on of the low doses of quetiapine (Seroquel) significantly decreases impaired impulse control in remitted patients with bipolar affective disorders both in self-evaluation and in risk-taking experimental test. The drop of high level of impulsivity can improve the quality and stability of remission and reduce behavioral risks due to impaired impulse control.

Keywords:

bipolar affective disorder
quetiapine
impulsivity
Seroquel
Barratt scale
Go-No-Go test
Balloon risk test

Authors:

Morozova M.A.

Centre for Mental Health Research

Potanin S.S.

Centre for Mental Health Research

Burminsky D.S.

Centre for Mental Health Research

Beniashvili A.G.

Centre for Mental Health Research

Rupchev G.E.

Centre for Mental Health Research

Lepilkina T.A.

Centre for Mental Health Research

Sorokin M.Yu.

Bekhterev National Research Center for Psychiatry and Neurology

Kasyanov E.D.

Bekhterev National Medical Research Center for Psychiatry and Neurology

Mazo G.E.

Bekhterev National Medical Research Center for Psychiatry and Neurology

Tarumov D.A.

Kirov Military Medical Academy

Trufanov A.G.

Kirov Military Medical Academy

Markin K.V.

Kirov Military Medical Academy

Beybalaeva T.Z.

Kazan State Medical University

Katok A.A.

Kazan State Medical University

Tsapko D.S.

Sechenov First Moscow State Medical University

Received:

10.06.2022

Accepted:

21.06.2022

List of references:

  1. Rote J, Dingelstadt A-M-L, Aigner A, et al. Impulsivity predicts illness severity in long-term course of bipolar disorder: A prospective approach. Aust N Z J Psychiatry. 2018;52(9):876-886.  https://doi.org/10.1177/0004867418783062
  2. Chamorro J, Bernardi S, Potenza M.N, et al. Impulsivity in the general population: A national study. Journal of Psychiatric Research. 2012;46(8):994-1001. https://doi.org/10.1016/j.jpsychires.2012.04.023
  3. Li C, Palka JM, Brown ES. Cognitive impairment in individuals with bipolar disorder with and without comorbid alcohol and/or cocaine use disorders. Journal of Affective Disorders. 2020;272:355-362.  https://doi.org/10.1016/j.jad.2020.03.179
  4. Henry C, Van den Bulke D, Bellivier F, et al. Affective lability and affect intensity as core dimensions of bipolar disorders during euthymic period. Psychiatry Research. 2008;159(1):1-6.  https://doi.org/10.1016/j.psychres.2005.11.016
  5. Ozten M, Erol A, Karayilan S, et al. Impulsivity in bipolar and substance use disorders. Comprehensive Psychiatry. 2015;59:28-32.  https://doi.org/10.1016/j.comppsych.2015.02.013
  6. Lima IMM, Peckham AD, Johnson SL. Cognitive deficits in bipolar disorders: Implications for emotion. Clinical Psychology Review. 2018;59:126-136.  https://doi.org/10.1016/j.cpr.2017.11.006
  7. Zetsche U, Joormann J. Components of interference control predict depressive symptoms and rumination cross-sectionally and at six months follow-up. Journal of Behavior Therapy and Experimental Psychiatry. 2011;42(1):65-73.  https://doi.org/10.1016/j.jbtep.2010.06.001
  8. Miskowiak K, Burdick K, Martinez-Aran A, et al. Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disorders. 2017;19(8):614-626.  https://doi.org/10.1111/bdi.12534
  9. Grande I, Berk M, Birmaher B, et al. Bipolar disorder. The Lancet. 2016; 387(10027):1561-1572. https://doi.org/10.1016/S0140-6736(15)00241-X
  10. Lan W-H, Bai Y-M, Hsu J-W, et al. Comorbidity of ADHD and suicide attempts among adolescents and young adults with bipolar disorder: A nationwide longitudinal study. Journal of Affective Disorders. 2015;176:171-175.  https://doi.org/10.1016/j.jad.2015.02.007
  11. Di Nicola M, Tedeschi D, Mazza M, et al. Behavioral addictions in bipolar disorder patients: Role of impulsivity and personality dimensions. Journal of Affective Disorders. 2010;125(1):82-88.  https://doi.org/10.1016/j.jad.2009.12.016
  12. Wright L, Lipszyc J, Dupuis A, et al. Response inhibition and psychopathology: A meta-analysis of go/no-go task performance. Journal of Abnormal Psychology. 2014;123(2):429-439.  https://doi.org/10.1037/a0036295
  13. Strakowski SM, Fleck DE, DelBello MP, et al. Impulsivity across the course of bipolar disorder. Bipolar Disorders. 2010;12(3):285-297.  https://doi.org/10.1111/j.1399-5618.2010.00806.x
  14. Meyer JM, Cummings MA, Proctor G, et al. Psychopharmacology of Persistent Violence and Aggression. Psychiatric Clinics. 2016;39(4):541-556.  https://doi.org/10.1016/j.psc.2016.07.012
  15. Ignácio ZM, Calixto AV, da Silva RH, et al. The use of quetiapine in the treatment of major depressive disorder: Evidence from clinical and experimental studies. Neuroscience & Biobehavioral Reviews. 2018;86:36-50.  https://doi.org/10.1016/j.neubiorev.2017.12.012
  16. Barzman DH, DelBello MP, Adler CM, et al. The Efficacy and Tolerability of Quetiapine versus Divalproex for the Treatment of Impulsivity and Reactive Aggression in Adolescents with Co-Occurring Bipolar Disorder and Disruptive Behavior Disorder(s). Journal of Child and Adolescent Psychopharmacology. 2006;16(6):665-670.  https://doi.org/10.1089/cap.2006.16.665
  17. Van den Eynde F, Senturk V, Naudts K, et al. Efficacy of Quetiapine for Impulsivity and Affective Symptoms in Borderline Personality Disorder. Journal of Clinical Psychopharmacology. 2008;28(2):147-155.  https://doi.org/10.1097/JCP.0b013e318166c4bf
  18. Dev V, Raniwalla J. Quetiapine. Drug-Safety. 2000;23(4):295-307.  https://doi.org/10.2165/00002018-200023040-00003
  19. Young RC, Biggs JT, Ziegler VE, et al. A Rating Scale for Mania: Reliability, Validity and Sensitivity. The British Journal of Psychiatry. 1978;133(5): 429-435.  https://doi.org/10.1192/bjp.133.5.429
  20. Montgomery SA, Åsberg M. A New Depression Scale Designed to be Sensitive to Change. The British Journal of Psychiatry. 1979;134(4):382-389.  https://doi.org/10.1192/bjp.134.4.382
  21. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. Journal of Clinical Psychology. 1995;51(6):768-774.  https://doi.org/10.1002/1097-4679(199511)51:6<768::AID-JCLP 2270510607>3.0.CO;2-1
  22. Enikolopov SN, Medvedeva TI. Approbation of the Russian-language version of the Barratt Impulsiveness Scale (BIS-11). Psychology and Law. 2015;5(3):75-89. (In Russ). https://doi.org/10.17759/psylaw.2015050307
  23. Tottenham N, Hare TA, Casey BJ. Behavioral assessment of emotion discrimination, emotion regulation, and cognitive control in childhood, adolescence, and adulthood. Front Psychol. 2011;2:39.  https://doi.org/10.3389/fpsyg.2011.00039
  24. Lejuez CW, Read JP, Kahler CW, et al. Evaluation of a behavioral measure of risk taking: The Balloon Analogue Risk Task (BART). Journal of Experimental Psychology: Applied. 2002;8(2):75-84.  https://doi.org/10.1037/1076-898X.8.2.75
  25. Psychtoolbox 3.0.11. Accessed February 01, 2022. https://psychtoolbox.org
  26. SPM12. Wellcome Centre for Human Neuroimaging | FIL | UCL. Accessed February 01, 2022. https://www.fil.ion.ucl.ac.uk
  27. Winter W, Sheridan M. Previous reward decreases errors of commission on later ‘No-Go’ trials in children 4 to 12 years of age: evidence for a context monitoring account. Developmental Science. 2014;17(5):797-807.  https://doi.org/10.1111/desc.12168
  28. Somerville LH, Bookheimer SY, Buckner RL, et al. The Lifespan Human Connectome Project in Development: A large-scale study of brain connectivity development in 5-21 year olds. NeuroImage. 2018;183:456-468.  https://doi.org/10.1016/j.neuroimage.2018.08.050
  29. CONN-fMRI toolbox 20.b. Accessed February 01, 2022. https://web.conn-toolbox.org
  30. Martuzzi R, Ramani R, Qiu M, et al. A whole-brain voxel based measure of intrinsic connectivity contrast reveals local changes in tissue connectivity with anesthetic without a priori assumptions on thresholds or regions of interest. NeuroImage. 2011;58(4):1044-1050. https://doi.org/10.1016/j.neuroimage.2011.06.075
  31. Harvard-Oxford atlas. Accessed February 01, 2022. https://cma.mgh.harvard.edu
  32. Lauriola M, Panno A, Levin I.P, et al. Individual Differences in Risky Decision Making: A Meta-analysis of Sensation Seeking and Impulsivity with the Balloon Analogue Risk Task. Journal of Behavioral Decision Making. 2014;27(1):20-36.  https://doi.org/10.1002/bdm.1784
  33. MacLean RR, Pincus AL, Smyth JM, et al. Extending the Balloon Analogue Risk Task to Assess Naturalistic Risk Taking via a Mobile Platform. J Psychopathol Behav Assess. 2018;40(1):107-116.  https://doi.org/10.1007/s10862-017-9628-4
  34. Ramírez-Martín A, Ramos-Martín J, Mayoral-Cleries F, et al. Impulsivity, decision-making and risk-taking behaviour in bipolar disorder: A systematic review and meta-analysis. Psychol Med. 2020; 50(13):2141-2153. https://doi.org/10.1017/S0033291720003086
  35. Reddy LF, Lee J, Davis MC, et al. Impulsivity and Risk Taking in Bipolar Disorder and Schizophrenia. Neuropsychopharmacol. 2014;39(2):456-463.  https://doi.org/10.1038/npp.2013.218
  36. Hajek T, Alda M, Hajek E, et al. Functional neuroanatomy of response inhibition in bipolar disorders — Combined voxel based and cognitive performance meta-analysis. Journal of Psychiatric Research. 2013;47(12):1955-1966. https://doi.org/10.1016/j.jpsychires.2013.08.015

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.